The major goal of this project is to determine the extent to which changes in plasma levels of specific lipoproteins, lipoprotein subspecies, and apolipoproteins are associated with quantitative changes in coronary atherosclerosis during the course of a controlled four-year risk factor intervention program. The study groups consists of 300 patients admitted to Stanford University Medical Center for management of coronary artery disease (transluminal percutaneous coronary angioplasty, coronary artery bypass surgery, or medical treatment). Coronary angiography and computerized quantitation of non-bypassed or non-dilated coronary artery segments have been carried out at baseline on all subjects and will be repeated at four years following medical management (all subjects) and intensive multiple risk factor is being carried out under separate funding at Stanford. The special intervention program at Stanford includes improved nutrition, weight reduction, increased aerobic exercise, stress management, and individualized treatment including pharmacologic reduction of low density lipoprotein cholesterol, elimination of cigarette use, and reduction of hypertension. Initial lipoprotein analyses on all 300 subjects were performed one to three weeks after medical stabilization, or six weeks after surgery, and are being repeated annually during four year of follow-up. In addition, pre-treatment samples will be obtained on al subjects beginning HMG CoA reductase-inhibitor treatment. Subfractions of plasma very low density (VLDL), intermediate density lipoprotein (IDL), low density (LDL), and computer-based quantitation procedure. LDL and HDL subspecies are also measured by AII and B in plasma, and apo B in LDL are measured by immunoassay. Analysis of lipid make it possible to identify those lipoprotein parameters most closely involved in the disease process. The results will also indicate whether detailed measurements of specific lipoprotein subclasses and apolipoproteins are more informative that conventional lipid measurements in predicting changes in coronary artery disease and in assessing the effects of strategies directed at its prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL033577-05
Application #
3345592
Study Section
Clinical Trials Review Committee (CLTR)
Project Start
1988-12-01
Project End
1992-11-30
Budget Start
1988-12-01
Budget End
1989-11-30
Support Year
5
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Lawrence Berkeley National Laboratory
Department
Type
Organized Research Units
DUNS #
078576738
City
Berkeley
State
CA
Country
United States
Zip Code
94720
Badzioch, Michael D; Igo Jr, Robert P; Gagnon, France et al. (2004) Low-density lipoprotein particle size loci in familial combined hyperlipidemia: evidence for multiple loci from a genome scan. Arterioscler Thromb Vasc Biol 24:1942-50
Paganini-Hill, A; Dworsky, R; Krauss, R M (1996) Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women. Am J Obstet Gynecol 174:897-902
Miller, B D; Alderman, E L; Haskell, W L et al. (1996) Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 94:2146-53
Campos, H; Roederer, G O; Lussier-Cacan, S et al. (1995) Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol 15:1043-8
Superko, H R; Myll, J; DiRicco, C et al. (1994) Effects of cessation of caffeinated-coffee consumption on ambulatory and resting blood pressure in men. Am J Cardiol 73:780-4
Tribble, D L; Krauss, R M (1993) HDL and coronary artery disease. Adv Intern Med 38:1-29
Superko, H R; Haskell, W L; Krauss, R M (1993) Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 101:1-8
Vega, G L; Grundy, S M (1992) Occurrence of species of low-density lipoprotein with defective clearance in patients with primary moderate hypercholesterolaemia. J Intern Med 232:405-13
Vega, G L; Krauss, R M; Grundy, S M (1990) Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 227:81-94
Williams, P T; Krauss, R M; Vranizan, K M et al. (1989) Effects of exercise-induced weight loss on low density lipoprotein subfractions in healthy men. Arteriosclerosis 9:623-32

Showing the most recent 10 out of 13 publications